Your search for Atrasentan returned 1 results

Ligand: atrasentan INN: atrasentan Comments: Atrasentan (ABT-627) is an orally available, nonpeptide endothelin receptor antagonist. The stereochemistry represented here Clinical use: Atrasentan was assessed in a Phase 1/II clinical trial as a potential anti-cancer treatment Mechanism of action: Atrasentan is an antagonist of the endothelin A (ETA) receptor. The molecular machanism underlying anti Bioactivity comments: atrasentan, with the conclusion that the activity of the compound resides in the RRS enantiomer

1

Ligand search page
Target search page
Pharmacology search page